A Phase IV Study in Drug-Naive Patients With T2DM in China

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 304 participants.

Also called NCT03344341

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 304 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03344341
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03344341. Randomized; no masking; primary purpose treatment. Start 2017-12-15 (actual); primary completion 2019-05-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase IV Study in Drug-Naive Patients With T2DM in China
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Acarbose
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct03344341
Content hash
0242e3aed21ea83a4d59a3d8a61aa8784378b29a338a6b8484a36381503b0e7d